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Risk Stratification 
Non-Q Wave Myocardial Infarction 
Steven Borzak, MD,* and Howard S. Rosman, MD* 
Non-Q wave myocardial infarction is a distinct and changing clinical entity characterized hy lower 
initial mortality and a higher rate of reinfarction compared to Q wave infarction. Clinical and 
pathologic data suggest that the syndrome resuhs from transient or incomplete coronary occlusion 
resulting in an infarct which is smaller than when Q waves are present. High-risk patients can 
be identified during hospitalization, allowing for aggressive therapy aimed at revascularization. 
Relatively few clinical trials have examined initial therapy or secondaiy prevention in this group of 
patients. These studies are reviewed and management guidelines suggested. (Heniy Ford Hosp Med 
J 1991:39:256-62) 
I n 1919, Herrick (1) published a report of three patients who survived acute coronary thrombosis. He displayed the ECG 
of one patient where T-wave abnormalities, but no Q waves, 
were present. This was the first published illustration of what is 
now referred to as a non-Q wave myocardial infarction (MI). 
One year later, Pardee (2) described a patient with MI whose 
ECG initially demonstrated pathological ST segment elevation 
with subsequenl development of a "deep S" wave. For decades 
this deep S wave (later called a Q wave) was the finding clini-
cians considered pathognomonic of infarction. 
In 1942, Langendorf and Kovitz (3) reported a patient with 
clinical evidence of Ml after hip surgery, where ECGs failed 
to show Q waves. At autopsy, the zone of infarction did not in-
volve the endocardium, leading the investigators to postulate 
that ST and T-wave changes in the absence of Q waves were 
markers for subendocardial infarction. In 1954, Prinzmetal et al 
(4) suggested that the subendocardium was relatively "silent" 
electrocardiographically in dogs subjected to experimental isch-
emia. This report advanced the practice of referring to infarc-
tions with Q waves as "transmural" and to infarctions with ST 
or T-wave changes but no Q waves as "subendocardial." Later 
findings by the same group invalidating the initial results went 
unnoticed (5). This terminology persisted despite clear evi-
dence, most recently assembled by Spodick (6), that extent of 
infarction does not correlate with presence or absence of Q 
waves. Therefore, most investigators currentiy classify infarc-
tions into electrocardiographic categories of "Q" versus "non-
Q" rather than using the imprecise pathologic descriptors of 
"transmural" versus "nontransmural." 
pathogenesis of infarction, rather than a secondary event. They 
performed eariy angiography in patients with infarction, which 
revealed a high incidence of thrombosis. In contrast, in 1986 the 
same group analyzed eariy angiograms of patients with non-Q 
wave Ml and showed a much lower incidence of coronary occlu-
sion and a higher incidence of collateralization of the infarct 
vessel (8). The finding of a patent infarct vessel has been re-
ported by other groups when patients were studied within two 
weeks after non-Q wave Ml (9,10). Pathologic studies con-
ducted by Davies and Thomas (11) have revealed that plaque 
fissure is common in initiating the sequence of events triggering 
the coagulation cascade and leading to thrombosis at the site of 
a fixed coronary obstruction. 
Reconciling the evidence of coronary thrombosis as the prox-
imate cause of infarction with catheterization studies in patients 
showing open infarct-related arteries after non-Q wave MI has 
led to several hypotheses on the mechanism of non-Q wave MI 
(Table 1). The angioscopic visualization of dynamic, forming, 
and dissolving thrombus in the coronaries of patients with "in-
termediate" and unstable coronary syndromes (12) suggested 
that not all intracoronary thrombi are permanent and has led to 
the favored hypothesis that non-Q wave Ml may be most often 
the result of transient coronary occlusion by thrombus. 
A number of lines of evidence have been marshalled by Gib-
son (13) favoring coronary occlusion followed by reperfusion as 
the most common mechanism of non-Q wave MI. First, patho-
logic studies by Freifeld et al (14) showed that patients dying of 
non-Q wave MI more often had patent infarct vessels and were 
Pathophysiology 
In 1980, DeWood and colleagues (7) settled a long-standing 
controversy by proving coronary thrombosis causative in the 
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Table 1 
Proposed Pathophysiological Mechanisms 
of Non-Q Wave Myocardial Infarction 
Occlusion-repert'usion of infarct vessel: 
• Spontaneous lysis of obstructive coronary thrombus 
• Relief of spasm which had cau,sed coronary occlusion 
• Both 
Incomplete occlusion of infarct vessel by plaque/thrombus 
Increased demand in setting of fixed coronary obstruction 
Occlusion of infarct vessel with low-grade collateral flow 
twice as likely to manifest contraction band necrosis, a histo-
logic feature of reperfusion, when compared with patients dying 
of similar-sized Q wave infarcts. Second, non-Q wave Mls tend 
to be smaller, with an earlier peak of serum creatine kinase MB 
(CK-MB), a serologic pattem suggesting "washout" of the en-
zyme in a reperfused zone similar to that observed after success-
ful treatment with thrombolytic agents (13). One trial reported 
that of 53 consecutive patients given streptokinase (SK) for 
acute chest pain and ST elevation on the ECG, eight ultimately 
developed non-Q wave Ml; six of the eight were treated within 
1.5 hours of the onset of symptoms (15). Finally, Huey and col-
leagues (9) showed that up to one-half of patients who ulti-
mately develop non-Q wave Ml without thrombolytic treatment 
present with ST elevation on the initial ECG, a pattem previ-
ously thought to lead inevitably to Q wave development. These 
findings have subsequently been confirmed by others (10,16, 
17). While it could be argued that ST elevation may not signify 
complete coronary occlusion, this finding together with the 
above arguments and other insights gained since the advent of 
the "thrombolytic era" suggest that non-Q wave MI differs from 
Q wave Ml not as much in the initiating sequence of intracoro-
nary thrombosis but more in the subsequent fate of the occlud-
ing thrombus. These studies also suggest that early thrombolytic 
therapy may "convert" a potential Q wave infarction into a non-
Q wave MI. Thus, patients with non-Q wave MI in the 1990s 
may be a different group than those studied in earlier years, be-
fore the general use of the more sensitive and specific CK-MB 
enzyme assay to detect infarction (early 1980s) (18,19) and 
prior to the increased application of thrombolytic therapy (mid 
1980s). This may explain why the incidence of non-Q wave Ml 
is increasing (18,20); non-Q wave Ml patients now account for 
more than 40% of all patients with MI at some institutions (21). 
Further research may help define anatomic, hematologic, and 
demographic characteristics that produce the differing rates of 
acute coronary occlusion in the Q wave and non-Q wave MI 
syndromes. 
Natural History and Clinical Syndrome 
of Non-Q Wave MI 
ECG criteria for non-Q wave MI 
Q wave infarctions are characterized by the development of 
30-msec or longer Q waves in at least two consecutive leads of 
the anterior (V1-V4), inferior (II, III , aVF), or lateral (1, aVL, 
Table 2 
Clinical Profile of Q Wave Versus 
Non-Q Wave Myocardial Infarction Patients* 
QWave 
MI 
Non-Q 
Wave MI 
Number 
of Studies 
Short-term mortality 
(5 to 30 days) 
Long-term mortality 
(12 to 96 months) 
Reinfarction 
(hospital stay-44 months) 
209; 10% 
31% 
16% 
24 
21 
14 
*Pooled data from Gibson (13), 
MI = myocardial infarction. 
V5, V6) distributions. Posterior infarctions characterized by 
prominent R waves and R/S ratio > 1 in leads VI-V2 are usually 
categorized as Q wave equivalent, as are anterior infarctions 
where "embryonic" R waves of less than 0.25 mm develop in 
VI-V4 (22). Presenting ECGs of patients with non-Q wave in-
farction may show initial ST elevation (9,10,16,17), in which 
case the diagnosis of non-Q wave MI must await subsequent 
evolution of the ECG over 24 to 48 hours. Patients with pro-
longed chest pain and ST depression or T-wave inversion on the 
initial ECG may initially be suspected of having non-Q wave 
MI. but distinction from unstable anginal syndromes must await 
serologic confirmation of infarction by CK-MB determination 
and clinical course. 
Clinical course and prognosis of non-Q wave MI 
Course and prognosis differ between patients who do and do 
not manifest Q waves after infarction. The many studies com-
paring clinical characteristics of Q wave and non-Q wave MI pa-
tients published between 1970 and 1983 have been extensively 
reviewed by Gibson (13). Appreciable differences have not been 
found regarding patients' demographic characteristics. The key 
question posed by nearly all of the studies is: Does the prognosis 
of Q wave and non-Q wave MI patients differ in terms of death 
or reinfarction? The synthesis of Gibson's review of these stud-
ies is shown in Table 2. Event rates for mortality and reinfarc-
tion were obtained by pooling the results in Q wave and non-Q 
wave MI groups. Not all studies showed a statistically signifi-
cant difference between groups for the variables shown, but ag-
gregate differences are highlighted. Non-Q wave MI patients 
had lower short-term mortalily (10% versus 20%) but similar or 
slightiy higher long-term mortality (32% versus 26%). This dis-
crepancy may be explained by the fact that nearly every study 
reviewed showed that non-Q wave Ml patients have a smaller-
sized infarct. More frequent reinfarction in non-Q wave MI 
(16% versus 6% in Q wave MI), sometimes fatal, would tend to 
equalize the long-term mortality rates. 
In-hospital Evaluation of Non-Q Wave 
MI Patients: Risk Assessment 
Patients with non-Q wave MI are a heterogeneous group re-
garding demographic characteristics, prior cardiac symptoms. 
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underlying coronary anatomy, ventricular function impairment, 
and, in particular, risk for future events (21). Some clinicians 
recommend lhal all non-Q wave Ml patients undergo coronary 
angiography with consideration toward revascularization (23), 
while others suggest that a noninvasive assessment can identify 
patients at lower risk for death and reinfarction who would then 
be managed expectantly without routine angiography (13,24). 
We recommend the latter approach, based on I) the lack of clini-
cal trials showing benefit to patients of one approach over the 
other, and 2) the results of several trials of thrombolytic therapy 
in patients presenting with ST segment elevation. The Throm-
bolysis in Myocardial Infarction, phase IIB (TIMI-IIB) study 
showed that in patients who had been treated with thrombolysis, 
a group which differs somewhat from patients with non-Q wave 
Ml, no benefit was achieved by requisite angiography and per-
cutaneous transluminal coronary angioplasty (PTCA) in the ab-
sence of recurrent ischemia (25). 
Recurrent or provokable ischemia 
Numerous studies have shown that recurrent spontaneous or 
provoked ischemia dramatically increases the risk of early rein-
farction and death in patients after a Q wave or an unspecified 
type of infarction (26). Similarly, in patients with non-Q wave 
MI, spontaneous postinfarction angina has been identified as a 
powerful predictor of subsequent events. Analysis of clinical 
features of the 576 patients enrolled in the multicenter Diltiazem 
Reinfarction Study (DRS) (22) revealed that the 43% of patients 
who had recurrent angina during the 14-day in-hospital follow-
up period had a nearly fourfold higher risk of reinfarction 
(12.2% versus 3.6%) and death (6.1% versus 1.5%) when com-
pared with patients not experiencing angina (27). Furthermore, 
patients whose angina was associated with ST or T-wave 
changes were 3.8 times more likely to have reinfarction and 7.5 
times more likely to die compared to patients with angina not 
manifesting transient ECG changes (27). Reinfarction itself was 
also a powerful predictor of in-hospital death: 16.7% of patients 
with reinfarction died as compared to 2.4% of patients without 
reinfarction (22). When comparing all non-Q wave Ml patients, 
Maisel et al (28) also found that patients with reinfarction had a 
higher in-hospital mortality (43% versus 8%) and one-year mor-
tality (65% versus 16%) than those without reinfarction. 
Evidence of ischemia provoked by predischarge submaximal 
exercise testing is also a predictor of increased risk of f uture car-
diac events. In a prospective study of 87 patients with non-Q 
wave MI, Gibson et al (10) found that 36% of patients had ST 
depression, 30% had angina, and 60% had a redistribution thal-
lium defect on submaximal predischarge treadmill testing. Sub-
sequently, over a median duration of 30 months of follow-up, 14 
ofthe 16 reinfarctions involved the infarct zone and all occurred 
in patients whose predischarge study had a redistribution thal-
lium defect (10). 
Anterior versus inferior-lateral location 
Several studies have shown that patients with anterior non-Q 
wave MI are more likely to experience future adverse events. 
Kao et al (21) analyzed consecutive cardiac care unit admissions 
and found that in 135 patients, anterior non-Q wave Ml location 
had a 3.8-fold relative risk of death and a 4.1-fold risk of rein-
farction compared with inferior-lateral location. In a retrospec-
tive analysis of patients in the Multicenter Investigation of the 
Limitation of Infarct Size study. Stone et al (29) confirmed that 
anterior location conferred a worse prognosis than inferior loca-
tion, even when data were adjusted to compare infarcts of simi-
lar size as determined by magnitude of peak CK release. Kao 
and colleagues (21) hypothesized that anterior infarcts in the left 
anterior descending (LAD) artery distribution may be more 
likely to have larger areas of residual ischemic myocardium than 
infarcts in the inferior location with the smaller distribution 
zones of right or left circumflex arteries. In addition, congestive 
heart failure, another risk factor for mortality, is more likely to 
occur at presentation or develop in the setting of an anterior in-
farct (29). 
Impaired ventricular function 
Clinical signs of heart failure as well as objective evidence of 
diminished ejection fraction are correlated with adverse out-
comes following non-Q wave MI (17,29,30). Congestive heart 
failure was a univariate predictor of reinfarction and mortality in 
the 576 patients enrolled in the DRS. and this variable remained 
an independent predictor of both outcomes after Cox multiple 
regression analysis (30). Subset analysis of the Multicenter Dil-
tiazem Postinfarction Trial dichotomized patients based on the 
presence or absence of pulmonary congestion and revealed that 
this clinical finding was a risk factor for reinfarction and cardiac 
death following non-Q wave MI. Furthermore, diltiazem admin-
istration led to an increa.se in death and reinfarction compared 
with placebo in this subset of patients (31). These findings sup-
port the already established importance of left ventricular (LV) 
function as the best predictor of outcome in patients with Q 
wave or unspecified infarction (26). 
Electrocardiographic findings 
A numberof studies have shown that non-Q wave MI patients 
whose initial ECGs manifest ST depression are at greater risk 
of death or reinfarction (16.30,32,33). One-year mortality was 
29%' versus 11 % when ST depression versus ST elevation was 
found on the initial ECG (16). However, initial ST depression 
often coexists with LV functional impairment (32,33). To inves-
tigate whether ST depression was an independent predictor of 
adverse outcome, Schechtman and colleagues (30) using Cox 
multiple regression analysis identified baseline and discharge 
ST depression as univariate predictors of one-year reinfarction 
and mortality but not of in-hospital reinfarction or mortality in 
the DRS population (31). The finding of persistent ST depres-
sion was the single most powerful independent predictor of both 
endpoints among all 24 variables examined. ST elevation pre-
sent at discharge also predicted late mortality but not reinfarc-
tion. 
The electrocardiographic diagnosis of LV hypertrophy has 
been shown in population-based studies to be independently as-
sociated with an increased risk of sudden death and acute MI 
(34). This relationship was confirmed in the non-Q wave MI 
population, where multivariate analysis of the DRS study popu-
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Table 3 
Clinical Predictors of Death or Reinfartion 
Death Reinfarction References 
Angina Angina 19,22 
Anterior location Anterior location 21,29 
CHF CHF 17,21,31 
ST depression ST depression 16,31,33,34 
LVH LVH 17,31 
Reinfarction 22,28 
Positive predischarge ETT 10 
CHF = congestive heart failure, LVH 
treadmill lesl. 
left ventricular hypertrophy, ETT : 
lation showed a twofold higher incidence of death and reinfarc-
tion at one-year follow-up (31). 
Diagnostic Approach to the Non-Q Wave 
MI Patient 
A recommended approach for diagnostic evaluation of the 
non-Q wave MI patient is based on the concept of risk stratifica-
tion (Table 3). This scheme is illustrated in the Figure. This ap-
proach would allow for expectant management of an uncompli-
cated patient at lower risk, while providing an aggressive pos-
ture when death or reinfarction is relatively more likely. We do 
note that no prospective study has shown improved clinical out-
comes after revascularization, whether by coronary artery by-
pass grafting (CABG) or PTCA in non-Q wave Ml patients. 
Nevertheless, a consensus favors such mechanical intervention 
when severe or unstable symptoms or high-risk clinical situa-
tions are present (13,23,24). 
Bedside assessment 
An especially vigilant approach is warranted given the ten-
dency for non-Q wave MI patients to experience recurrent an-
gina, infarction, and death as described previously. In particular, 
patients should be questioned daily about the development of 
ischemic or congestive heart fatiure symptoms. The physical ex-
amination should focus on the development of tachycardia, hy-
potension, pulmonary rales, or new gallop rhythms. A subtie de-
terioration in ventricular function in a resting, asymptomatic pa-
tient may be the only sign of recurrent ischemia or infarction. 
The appearance of any of these findings justifies a repeat ECG to 
look for new ischemic changes. 
History of chest 
pain after >24 
hours 
ST-T changes 
compatible with 
ischemia 
Development of signs or 
symptoms of CHF: EF 
<50% 
Anterior infarction 
Ventricular tachycardia 
or fibrillation 
Predischarge ETT 
positive for ischemic 
Catheterization Close observation Catheterization 
Figure—Algorithm for in-hospital evaluation (rf the non-Q 
wave MI patient. The treatment strategy is based on the pres-
ence or absence of high-risk clinical markers. See text for de-
tails. 
While the appearance of complex ventricular ectopy was 
found to occur in 22% of non-Q wave MI patients in one series, 
this study did not differentiate sustained or symptomiatic ven-
tricular tachycardia or fibrillation from lower grade arrhyth-
mias, nor did it find that ventricular ectopy predicted subsequent 
events (10). However, the small sample size of this subgroup 
makes a type II error possible. Because late (occurring after the 
first 24 hours) sustained or symptomatic ventricular tachycardia 
or fibrillation occurring in the absence of electrolyte disturbance 
or severe LV dysfunction may signify ischemia, we feel that this 
set of circumstances warrants coronary angiography. Continu-
ous bedside and/or bolter monitoring is recommended for the 
first 48 to 72 hours after symptom onset (35). 
The submaximal exercise test has become the standard of care 
for MI patients prior to discharge who do not experience an in-
hospital complication (26). If resting ST abnormalities such as 
LV hypertrophy or digitalis effect preclude interpretation of ex-
ercise-induced ECG changes, then thallium imaging is recom-
mended (35). Patients who manifest ischemia by the develop-
ment of angina, ECG changes, or diagnostic thallium alterations 
can then be referred for angiography. 
Noninvasive assessment 
Since significant impairment of LV function can be asympto-
matic or compensated by medical therapy, we believe an objec-
tive assessment of LV function by echocardiography or radio-
nuclide ventriculography is warranted prior to discharge. Pa-
tients with impaired LV function are more likely to have mul-
tivessel coronary disease and would be most likely to benefit 
from mechanical revascularization (35). 
Invasive assessment 
Once a patient has been identified as high risk, catheterization 
with coronary angiography is recommended (Table 4). The goal 
of this procedure is to define coronary anatomy in consideration 
of revascularization by PTCA or CABG. Accordingly, a relative 
contraindication to catheterization would be a patient's unwill-
ingness to consider either revascularization procedure. 
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Table 4 
In-hospital Evaluation of Patients with 
Non-Q Wave Myocardial Infarction 
Procedure Inclusion Purpose 
Daily bedside All patients Assess for recurrent 
examination angina or CHF 
Telemetry or Holler All patients Detect "late" ventricular 
monitoring (at least tachycardia or fibrillation 
72 hours) 
Echocardiography or All patients Determine overall ventricular 
radionuclide function and regional 
ventriculogram contractility 
Predischarge ECG Patients without Detect persistent or new 
prior indication ST depression 
for angiography 
Submaximal Patients without Detect exercise-induced 
predischarge prior indication ischemia 
exercise test for angiography 
Coronary angiography See Figure Define coronary anatomy prior 
to possible revascularization 
Treatment of Non-Q Wave MI Patients 
Thrombolytic therapy 
No study to date has conclusively reported the effect of 
thrombolytic therapy on death or reinfarction after non-Q wave 
Ml. Such a study might be impossible to conduct because ofthe 
variability in presenting features seen in non-Q wave MI pa-
tients. Up lo one-half of non-Q wave MI patients present with 
ST elevation on ECG, which is a general criterion for admini-
stration of thrombolytic therapy (25). Many patients who later 
develop a non-Q wave MI might initially be classified as having 
a transmural injury currentiy typical of an evolving Q wave in-
farct (9). Non-Q wave MI patients presenting with ST depres-
sion or T-wave inversion cannot be reliably distinguished from 
patients with unstable angina until CK-MB results and clinical 
course are apparent. The TIMI-IIIB study currentiy in progress 
is designed to compare low-dose tissue plasminogen activator 
with placebo in patients with chest pain and ECG changes other 
than new ST elevation or Q waves, but without enzymatic evi-
dence of infarction; some of these patients are likely to develop 
non-Q wave Ml. Thus non-Q wave MI patients are now more 
likely either to be given lytic therapy upon presentation with ST 
elevation or be managed without thrombolysis if presenlalion is 
with ST depression or T-wave inversion. Recommendations for 
lytic therapy in the latter group of patients must await the results 
of TIMI-llIB and other trials. 
Heparin and acetylsalicylic acid 
No trial has examined the role of either intravenous (IV) hep-
arin or acetylsalicylic acid (ASA) as primary treatment for pa-
tients with non-Q wave MI. Lxtw-dose subcutaneous heparin has 
been recommended after infarction to prevenl venous thrombo-
sis and pulmonary embolism (35). Therapeutic IV heparin has 
been shown to be of benefit in unstable angina (22), and since a 
common pathophysiology has been proposed for unstable an-
gina and non-Q wave MI (36), some investigators have advo-
cated the use of this agent on presentation and for several days 
after non-Q wave MI. Heparin may be even more appealing with 
the knowledge that most infarct-related vessels are patent at 
angiography and that most reinfarctions occur in the same arte-
rial distribution (10), but a firm recommendation cannot be 
made in the absence of a clinical trial. IV heparin followed by 
oral anticoagulation can be recommended when non-Q wave Ml 
is accompanied by severe global hypokinesis, significant ante-
rior akinesis, or directiy visualized mural thrombus (35). 
ASA has been shown to reduce mortality and reinfarction in 
unstable angina (37), but no trial has assessed prospectively its 
effect on modifying myocardial damage in patients with non-Q 
wave MI. Again, based on the postulated common pathophysi-
ologic mechanisms of these two clinical entities, early ASA 
therapy is appealing. A much stronger argument can be made for 
ASA treatment in secondary prevention of future events. 
Anti-ischemic therapy 
Recurrent angina after non-Q wave MI should be promptiy 
treated, followed by coronary angiography. There is littie to 
suggest relative benefits of calcium channel blocking agents 
over (3-adrenergic receptor blocking agents (beta-blockers) 
when ischemia recurs in the days after non-Q wave MI. 
IV nitroglycerin has found growing support for its potential 
role in limiting infarct size and reducing mortality in patients 
with unspecified infarction (38,39). However, no study has ad-
dressed the non-Q wave MI population and current recommen-
dations of the American College of Cardiology do not support 
IV nitroglycerin in all patients with infarction (35). Nitroglyc-
erin is well established for relieving ischemic symptoms. Anal-
gesia with morphine sulfate and sedation with short-acting ben-
zodiazepines are appropriate for many patients experiencing an-
gina. 
Revascularization 
No study has examined the effect of either PTCA or CABG 
on symptoms or survival after non-Q wave MI. When recurrent 
ischemia or infarction occurs, there is general agreement among 
cardiologists that catheterization followed by mechanical revas-
cularization offers the best hope both for relief of symptoms and 
protection from further ischemia and infarction (13,24). Such an 
approach is particularly warranted when the jeopardized myo-
cardium is in the anterior distribution of the LAD artery (16). 
Secondary Prevention After Non-Q Wave MI 
An important issue distinct from management of recurrent 
ischemia is routine prophylactic treatment of patients who are 
asymptomatic after non-Q wave MI (Table 5). 
ASA and anticoagulation 
ASA has been shown in a number of trials to reduce both 
death and reinfarction after unspecified infarction and should be 
given to patients after non-Q wave MI when no contraindica-
tions are present (37). Subgroup analysis of the Persantine-As-
pirin Reinfarction Study suggested that the beneficial effects of 
antiplatelet therapy may be even more pronounced for non-Q 
wave MI than for Q wave Ml patients (40). 
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Table 5 
In-hospital Treatment of Non-Q Wave 
Myocardial Infarction Patients* 
Status of 
Indication Treatment Recommendation 
Primary modification Thrombolytic therapy Controversial 
of infarction Heparin Controversial 
ASA Recommended 
Nitrates Acceptable 
Beta-blockers Acceptable 
Calcium blockers Controversial 
Secondary prevention of ASA Recommended 
death or reinfarction Beta-blockers Acceptable 
Calcium blockers Acceptable 
Warfarin Controversial 
*For references, see text. 
While anticoagulation with warfarin was shown in a recent 
study to reduce death after unspecified infarction (41), routine 
administration to non-Q wave Ml patients cannot be recom-
mended in the absence of more traditional indications (visual-
ized mural thrombus, akinetic anterior wall, atrial fibrillation). 
Calcium channel blockers and the DRS 
The DRS is the only published trial designed to examine sec-
ondary prevention specifically in the population of non-Q wave 
MI patients (22). A total of 576 patients were enrolled 24 to 72 
hours after the index event and randomized to the double-blind 
administration of diltiazem or placebo. Patients were followed 
until discharge (a total of 14 days) and evaluated for the primary 
endpoint of reinfarction and secondary endpoints of recurrent 
angina and in-hospital mortality. Diltiazem was found to reduce 
early reinfarction from 9.3% in control patients to 5.2% in those 
receiving diltiazem (P < 0.03). The validity of this finding has 
been questioned, however, because a one-sided test of signifi-
cance used in this analysis would not adequately account for the 
possibility of an adverse effect of treatment. Diltiazem had no 
significant effect on recurrent angina (41% versus 44% in pla-
cebo-treated patients) or on in-hospital mortality (3.8% versus 
3.1% in the placebo group). Episodes of severe angina (requir-
ing withdrawal from the trial for indicated calcium channel 
blockers or revascularization) were significantly reduced by 
50%. No late follow-up on treatment effect was provided in the 
study. We note also that nearly two-thirds of patients in both 
treatment and control groups were receiving beta-blockers, 
which were not restricted by the study design. 
A retrospective analysis of non-Q wave MI patients has been 
performed on results from the Multicenter Diltiazem Postinfarc-
tion Trial (31). This study was designed to examine the long-
term effects of diltiazem from 3 to 15 days after unspecified in-
farction, with follow-up to an average of 25 months. Diltiazem 
had no effect on mortality or cardiac event rate overall (42), but 
subgroup post hoc analysis showed fewer cardiac events and a 
trend toward lower mortality in patients receiving diltiazem af-
ter a first non-Q wave MI. A detrimental effect was seen in all 
subgroups with pulmonary congestion as a manifestation of 
congestive heart failure (31). However, retrospective subgroup 
analysis has serious limitations in identifying treatment indica-
tions not originally specified by the study design (43). 
Other calcium channel blocking agents (verapamil, nifedi-
pine, and newer "second generation" agents) have not been ex-
amined specifically in non-Q wave Ml patients. We conclude 
that data support the safe use of diltiazem for secondary preven-
tion after non-Q wave Ml in patients without congestive heart 
failure (35) but that unequivocal evidence of important benefit 
is lacking. 
Beta-blocking agents 
The use of beta-blocking agents after unspecified infarction 
has been found to reduce significantly both mortality and rein-
farction; their administration has been recommended for at least 
two years after a MI (35). No trial has prospectively examined 
the non-Q wave Ml population, but subset analysis of three 
studies—Metoprolol in Myocardial Infarction Study, the Beta-
Blocker Heart Attack Trial, and the Timolol Myocardial Infarc-
tion Study—has yielded conflicting results, with only the latter 
study showing a statistically significanl decrease in mortality 
but not reinfarction (44-46). The limitations of post hoc analysis 
have been extensively discussed in this context (43). Given the 
relative instability of the non-Q wave Ml population compared 
to patients with Q wave infarcts, some investigators have argued 
that prophylactic beta-blockade might in fact be more beneficial 
in this subgroup. An answer to this intriguing issue must await a 
prospective trial. 
Revascularization 
No trial supports PTCA or CABG in asymptomatic patients 
following non-Q wave MI (13). We support the use of the pre-
discharge treadmill test to direct patients who manifest exercise-
induced ischemia toward catheterization and revascularization 
when appropriate. 
Summary and Conclusions 
Changes in medical practice in the 1990s—among them a 
better pathophysiologic understanding of the role of intra-
coronary thrombus and increased use of thrombolytic therapy in 
the early hours of MI— h^ave changed the types and numbers of 
patients with the diagnosis of non-Q wave MI. Prior experience 
has shown that non-Q wave MI patients experience smaller in-
farcts, higher rates of reinfarction, and lower in-hospital mortal-
ity compared to Q wave MI patients. In-hospital management 
should focus on an aggressive search for spontaneous or pro-
vokable ischemia, depressed LV function, and other markers of 
increased risk of future events. Such patients should be consid-
ered for angiography and revascularization. Few clinical studies 
support specific secondary prevention strategies in this popula-
tion other than those measures recommended for the postinfarc-
tion population at large. Firm recommendations for therapy 
must await future trials. 
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